Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells

Código QR

Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells

Fernando Rodríguez-Serrano,1,* Nuria Mut-Salud,1,* Teresa Cruz-Bustos,2 Mercedes Gomez-Samblas,2 Esther Carrasco,1 Jose Manuel Garrido,3 F Javier López-Jaramillo,4 Francisco Santoyo-Gonzalez,4 Antonio Osuna2 1Institute of Biopathology and Regenerative Medicine, 2Molecular Bioc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rodríguez-Serrano F, Mut-Salud N, Cruz-Bustos T, Gomez-Samblas M, Carrasco E, Garrido JM, López-Jaramillo FJ, Santoyo-Gonzalez F, Osuna A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	targeted drug delivery doxorubicin HER2 nanoparticle paclitaxel protein A trastuzumab Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8b769a1a364c4f0a87fa343c7c143d50
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan AS, et al.
Publicado: (2021)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky M, et al.
Publicado: (2021)

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer
por: Rodallec A, et al.
Publicado: (2018)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021)

The Role of Trastuzumab in Patients with HER2 Positive Small (pT1mi/a) Breast Cancers, a Multicenter Retrospective Study
por: Andrea Villasco, et al.
Publicado: (2021)

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab
por: Nathalie I. Bouwer, et al.
Publicado: (2021)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato Y, et al.
Publicado: (2021)

Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models
por: Li Wen, et al.
Publicado: (2021)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Hye Ryeon Kim, et al.
Publicado: (2021)

Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab
por: Quagliariello V, et al.
Publicado: (2020)

Functionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy
por: Cruz-Bustos T, et al.
Publicado: (2012)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Belal Firwana, et al.
Publicado: (2012)

Data provision of PIK3CA gene diversity and recombinant plasmids preparation for control DNA in developing the trastuzumab predictive response diagnostic kit
por: DESRIANI DESRIANI, et al.
Publicado: (2016)

Características clínicas y pronóstico de pacientes con cáncer de mama HER2 positivo avanzado, en la era antes y después de terapias anti-HER2
por: SÁNCHEZ,CESAR, et al.
Publicado: (2018)

Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer
por: Haruka Yamaguchi, et al.
Publicado: (2021)

Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma
por: Xiu Liu, et al.
Publicado: (2021)

Development of anti-HER2-targeted doxorubicin–core-shell chitosan nanoparticles for the treatment of human breast cancer
por: Naruphontjirakul P, et al.
Publicado: (2019)

Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles
por: Colzani B, et al.
Publicado: (2018)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
por: Phung HT, et al.
Publicado: (2020)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar I, et al.
Publicado: (2021)

Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab
por: Martins,Sandro José, et al.
Publicado: (2012)

99mTc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer
por: Rainone P, et al.
Publicado: (2021)

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer
por: Rodallec A, et al.
Publicado: (2018)

Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac
por: Sudha T, et al.
Publicado: (2017)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Diana B. Peckys, et al.
Publicado: (2021)

HER2 overexpression is a putative diagnostic and prognostic biomarker for late-stage colorectal cancer in North African patients
por: Eman A. Abdul Razzaq, et al.
Publicado: (2021)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Matteo Allegretti, et al.
Publicado: (2021)

Estudos clínicos randomizados para registro de biossimilares trastuzumabe: uma revisão de escopo, Brasil, 2020
por: Tamiris Fazza Kelmer, et al.
Publicado: (2021)

Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells
por: Wu C, et al.
Publicado: (2017)

HER2/neu Status in Breast Cancer Specimens: Comparison of Immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) Methods
por: Saglican,Yesim, et al.
Publicado: (2015)

Inhibition of Glioma Cells’ Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics
por: Thakur A, et al.
Publicado: (2020)

A Importância do Monitoramento e da Identificação Precoce de Cardiotoxicidade do Tratamento com Trastuzumabe no Câncer de Mama: Relato de Caso
por: Patricia Marques Soares Valente, et al.
Publicado: (2019)

Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo
por: Duan D, et al.
Publicado: (2018)

Expresión y amplificación del gen HER2 en el cáncer gástrico avanzado
por: Roa,Iván, et al.
Publicado: (2013)

Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio
por: Marjorie Coimbra Roque, et al.
Publicado: (2021)

Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity
por: Esteban Cruz, et al.
Publicado: (2021)

Polymer–lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells
por: Li J, et al.
Publicado: (2017)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
por: Puhalla S, et al.
Publicado: (2016)

Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
por: Kustic,Domagoj, et al.
Publicado: (2019)

A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer
por: Yalikong A, et al.
Publicado: (2021)